Ernexa Therapeutics Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Cambridge, MA
ERNA chart
What traders are saying about $ERNA
Latest postsErnexa Therapeutics Inc. news
- Ernexa Therapeutics Inc. (ERNAW) Seasonal returns chart
Yahoo Finance UK ·
- Ernexa Therapeutics Reports $12.5M Net Loss and Goodwill Impairment in Q3 2026
Kalkine Media ·
- Nine-month operating cash use rises to $9.6M as Ernexa Therapeutics (ERNA) faces a funding gap.
Stock Titan ·
- Ernexa Therapeutics Inc. (ERNA) stock price, news, quote and history
Yahoo Finance Singapore ·
- Ernexa Therapeutics (ERNA) Stock Price, News & Analysis
MarketBeat ·
- Ernexa Therapeutics (ERNA) FDA Approvals, PDUFA Dates & Drug Alerts 2026
MarketBeat ·
- ERNA Q3'26 Earnings: EPS estimate is (3.84) USD
TradingView ·
- Ernexa Therapeutics Highlights ERNA-101’s Path Toward the Clinic and Differentiated Cell Therapy Platform in New “What This Means” Segment
Yahoo Finance ·
- Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series
Yahoo Finance ·
- Ernexa Therapeutics’ ERNA-101 Selected for Flash Talk Presentation at Nature Conferences’ Next-Generation Cancer Therapeutics Meeting Co-Hosted by MD Anderson Cancer Center
Yahoo Finance ·
- Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the Clinic
Yahoo Finance ·
- Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND
Yahoo Finance ·
Ernexa Therapeutics Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | – | $582,000 | $68,000 | $0 |
| Net income | -$14.1M | -$44.5M | -$21.7M | -$24.6M |
| Diluted EPS | $-2.24 | $-48.96 | $-4.08 | $-8.06 |
| Total assets (year end) | $5.8M | $5.3M | $49.1M | $22.3M |
| Cash and equivalents (year end) | – | $1.7M | $7.6M | $11.4M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Ernexa Therapeutics Inc.
- Ticker
- ERNA (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Cambridge, MA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 748592
- Former names
- Eterna Therapeutics Inc., Brooklyn ImmunoTherapeutics, Inc., NTN BUZZTIME INC
Frequently asked questions
What exchange is Ernexa Therapeutics Inc. listed on?
Ernexa Therapeutics Inc. trades on the Nasdaq under the ticker symbol ERNA.
What industry is Ernexa Therapeutics Inc. in?
Ernexa Therapeutics Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Ernexa Therapeutics Inc. headquartered?
Ernexa Therapeutics Inc.'s business address on file with the SEC is in Cambridge, MA.
When does Ernexa Therapeutics Inc.'s fiscal year end?
Ernexa Therapeutics Inc.'s fiscal year ends on December 31.
How much revenue did Ernexa Therapeutics Inc. report?
Ernexa Therapeutics Inc. reported $582,000 in revenue for calendar year 2024, according to its SEC filings.